NCT06939257 Pain Outcomes Associated With Exogenous Hormone Therapy in Adults
| NCT ID | NCT06939257 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Kansas Medical Center |
| Condition | Pain |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2025-03-31 |
| Primary Completion | 2029-09-16 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2025-03-31 with a primary completion date of 2029-09-16.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
TRANSPIRE is an observational study of \~200 individuals who (1) will be initiating gender-affirming hormone therapy (GHT) or (2) are gender minority individuals who do not use GHT. The primary outcome will be to identify how the presence of chronic pain changes overtime with GHT through the use of surveys, quantitative sensory testing (QST), brain MRIs, and qualitative interviews. Following recruitment and consent, participants will complete baseline survey measures and will repeat those measures at 1 months, 3 month, 6 months, and 12 months. QST measures, brain MRIs, and Qualitative Interviews will be offered to participants in cohort (1) and will be completed at baseline and 12 months.
Eligibility Criteria
Inclusion Criteria: * Informed consent provided by the participant * Ages 18-50 years * English speaking * GM persons who have been deemed to be an appropriate medical candidate to take gender-affirming hormone therapy for gender incongruence -OR- GM persons who are not taking gender-affirming hormone therapy Aim 2 (QST and MRI) Additional Inclusion Criteria: * GM persons who have been deemed to be an appropriate medical candidate to take gender- affirming hormone therapy for gender incongruence * Stable doses of analgesic medications for at least 30 days prior to screening * Right handed * Normal visual acuity or correctable to at least 20/40 for reading instructions in the MRI * Willingness to refrain from pain medications such as NSAIDs, acetaminophen, and opioid medications for 12 hours prior to neuroimaging and QST * Willingness to refrain from alcohol and nicotine on day of QST and neuroimaging * Willingness to refrain from physical activity or exercise that would cause muscle and/or joint soreness for 48 hours prior to testing (routine exercise or activity that does not lead to soreness is acceptable) * Investigators will attempt to recruit individuals with no chronic daily use of adjunctive pain medications, including tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors, and gabapentinoids as these drugs can influence neuroimaging and QST findings, or have individuals be weaned off of these meds at least two weeks prior to being studied. In previous smaller imaging studies investigators could accomplish this, but this may not be possible in this large of a study. If the study team does need to allow individuals into these cohorts while on such medications because of pragmatic issues, this information will be recorded and patients will be asked to remain on a stable dose for at least two weeks prior to MRI and QST assessments. * Able to lie still on their back for 1.5 hours for MRI scans Exclusion Criteria: * Inability to provide informed consent * Age less than 18 years or greater than 50 years * Severe physical impairment (e.g., blindness, deafness, paraplegia) * Co-morbid medical conditions that may significantly impair physical functional status (e.g., history of non-skin malignancy, or autoimmune disorder) * Pregnant or nursing * Liver failure * Self-reported liver cirrhosis * Self-reported hepatitis * Severe Cardiovascular disease (examples: history of myocardial infarction, unstable angina, severe coronary artery disease, congestive heart failure, or severe valvular abnormalities) that are self-reported by patient or by medical record * Prisoner * Current litigation for chronic pain * Current disability proceedings * Active psychotic or suicidal symptoms * Current drug or alcohol use disorder * History of gonadectomy surgery Aim 2 (QST and MRI) Additional Inclusion Criteria: * Contraindications to MRI (e.g., metal implants, pacemaker, etc.) * Severe claustrophobia precluding MRI and evoked pain testing during scanning * BMI \> 40 or unable to lie comfortably in MRI * Current, recent (within the last 6 months), or habitual use of artificial nails or nail enhancements. (Artificial nails can influence pressure pain sensitivity at the thumbnail) * Peripheral neuropathy * Diagnosed epilepsy or seizure history
Contact & Investigator
Andrea L Chadwick, MD, MSc, FASA
PRINCIPAL INVESTIGATOR
University of Kansas Medical Center
Frequently Asked Questions
Who can join the NCT06939257 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 50 Years, studying Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06939257 currently recruiting?
Yes, NCT06939257 is actively recruiting participants. Contact the research team at FACELab@kumc.edu for enrollment information.
Where is the NCT06939257 trial being conducted?
This trial is being conducted at Kansas City, United States.
Who is sponsoring the NCT06939257 clinical trial?
NCT06939257 is sponsored by University of Kansas Medical Center. The principal investigator is Andrea L Chadwick, MD, MSc, FASA at University of Kansas Medical Center. The trial plans to enroll 200 participants.